Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disoproxil fumarate

This page shows the latest tenofovir disoproxil fumarate news and features for those working in and with pharma, biotech and healthcare.

Gilead builds case for Descovy PrEP after FDA approval

Gilead builds case for Descovy PrEP after FDA approval

Descovy (emtricitabine/tenofovir alafenamide) claimed its  FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green

Latest news

  • Gilead claims FDA okay for Descovy as second PrEP option Gilead claims FDA okay for Descovy as second PrEP option

    Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing

  • MSD claims EU approval for two HIV products MSD claims EU approval for two HIV products

    The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,

  • ViiV chalks up another win for two-drug HIV regimen ViiV chalks up another win for two-drug HIV regimen

    effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... fumarate and emtricitabine – two

  • GSK two-drug trial in untreated HIV raises Gilead rivalry GSK two-drug trial in untreated HIV raises Gilead rivalry

    The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    The fixed dose combination of integrase strand inhibitor bictegravir with the two active ingredients in Descovy - emtricitabine and tenofovir alafenamide - met its main objective of non-inferiority to ViiV Healthcare's ... The drug is an upgrade to

More from news
Approximately 2 fully matching, plus 31 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....
OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...
Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....

Infographics